Register Now - Beyond Recruitment: The Future of Patient Site Engagement in Oncology Clinical Trials
News|Articles|October 11, 2023

Oxford-Harrington Rare Disease Center Introduces New Therapeutics Accelerator

Aims to advance innovative treatments for rare diseases.

The University of Oxford, in association with Harrington Discovery Institute at University Hospitals in Cleveland, announced the launch of the Oxford-Harrington Rare Disease Center Therapeutics Accelerator with an official signing event at the University of Oxford. According to a company press release, the accelerator is transatlantic initiative to identify, fund and advance breakthrough academic discoveries to deliver new treatments for the 400 million people worldwide who suffer from rare diseases.

"Harrington has been supporting the advancement of treatments for rare and other diseases for more than a decade, committing significant funds and resources to this global challenge with considerable success,” said Jonathan Stamler, MD, president, founder, Harrington Discovery Institute "Our commitment is to major unmet needs in society to better the world. This new Accelerator and extended collaboration with Oxford and Oxford Science Enterprises represents a major step forward towards finding the best medicines that improve outcomes for the millions of individuals and families affected by rare diseases."

Reference: The Oxford-Harrington Rare Disease Centre Launches Pioneering Therapeutics Accelerator to Advance Innovative Treatments for Rare Diseases. PR Newswire. October 3, 2023, Accessed October 10, 2023. https://www.prnewswire.com/news-releases/the-oxford-harrington-rare-disease-centre-launches-pioneering-therapeutics-accelerator-to-advance-innovative-treatments-for-rare-diseases-301945119.html


Related to this article

Closing the Community Access Gap: Q&A with Kent Thoelke, Paradigm Health
In this Q&A, Kent Thoelke, CEO of Paradigm Health, discusses why participation gaps in community and rural settings come down to both patient cost barriers and site infrastructure, how legacy workflows weigh on community clinics, and what policy and technology changes it would take to make clinical research a real care option for more patients.
© Grispb - © Grispb - stock.adobe.com
Mistral and OpenAI produced identical overall eligibility labels across 200 synthetic patient-study assessments, with criterion-level disagreements concentrated in inclusion criteria where models switch between “Uncertain” and “Not included” when records lack sufficient evidence, so model choice should be driven by deployment architecture, control, and cost rather than assumed interchangeability.
The Human Side of Clinical Trials: Before Burden Becomes Risk, Capturing Friction in Real Time
In Episode 4 of The Human Side of Clinical Trials, host Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., speaks with Jason Riis, PhD, CEO and chief behavioral scientist at Behavioralize, about how capturing friction closer to the moment it happens can reveal unclear instructions, technology friction, and workarounds that retrospective surveys and debriefs tend to miss.